SEC Form 4 · accession 0000905148-26-003960
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
AnhCo Nguyen
Officer — President and CEO · Director
Period of report
Aug 17, 2026
Accepted (ET)
Aug 26, 2026 · 7:45 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 17, 2026 | S | 5,062 | $8.0764 | D | 132,775 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
- F2The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 17, 2026, on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employees.
Remarks
Exhibit List: Exhibit 24 - Power of Attorney